In brief
- On October 5, the FDA issued a request for information on designing early-phase clinical trials for ibogaine.
- The agency suggests small dose-escalation cohorts, an initial dose not exceeding 10 mg/kg, and an inpatient hospital setting equipped for severe arrhythmias.
- Public comments are open through November 20, 2026, under docket FDA-2026-N-10429.
The US Food and Drug Administration (FDA) has opened a public consultation on how initial clinical trials with ibogaine should be designed. The agency outlines the approaches it is considering and invites stakeholders to submit feedback, data, and information before November 20.
What the agency is asking
The announcement, dated October 5, is organized into four core areas: general study design and patient populations; dose selection and escalation; safety considerations, with monitoring for cardiac and neurological events; and ethical and oversight issues, such as informed consent and independent safety monitoring. The notice was published in the Federal Register on October 6. Comments can be submitted via regulations.gov to docket FDA-2026-N-10429, open for 45 days following publication.
Dosing, setting, and cardiac safety
The Federal Register document is far more specific than the press release. For early trials, the FDA envisions dose-escalation cohorts with single-subject staggered dosing within each cohort. The starting dose must be justified by published scientific literature and should not exceed 10 mg/kg. Escalating to the next cohort would be evaluated following review by a safety committee, a data monitoring committee, and the FDA itself. The notice also suggests genotyping participants for CYP2D6, the liver enzyme responsible for metabolizing ibogaine into noribogaine.
Regarding the setting, the agency’s proposed designs would require an inpatient hospital unit fully equipped to manage life-threatening arrhythmias. This setup entails continuous cardiac telemetry, a clinical team led by a physician certified in Advanced Cardiac Life Support (ACLS), a bedside defibrillator, medications to treat torsades de pointes, emergency cardiac pacing, and mechanical ventilatory support. The document also notes that transient ataxia is common following ibogaine administration: in a prospective study of patients with opioid use disorder receiving a single 10 mg/kg dose, all participants experienced severe transient ataxia. Furthermore, it identifies a significant gap in the literature: whether ibogaine causes persistent neurological or cognitive impairment at clinically relevant doses has not been systematically investigated.
The director of the FDA’s Center for Drug Evaluation and Research, Michael Davis, summarized the approach by noting that there are “important scientific questions” alongside “serious safety concerns.” According to the agency, the Department of Health and Human Services (HHS) is prioritizing two patient populations for federally funded research: adults with opioid use disorder and adults with PTSD.
What this means
This notice is neither an approval nor binding regulatory guidance; it is a request for public feedback to determine whether and how to incorporate these considerations when reviewing investigational new drug (IND) applications for ibogaine. The FDA frames this initiative under the April 2026 executive order, highlighting other interconnected efforts: its final guidance on psychedelics issued in July, the cleared noribogaine trial for alcohol use disorder, the ARPA-H program, and NIDA funding. We previously covered this federal funding and the launch of the first federally funded ibogaine trials.
The request highlights the agency’s risk assessment: ibogaine is being treated as a compound with a cardiac risk profile that requires strict inpatient oversight during research, rather than as a conventional drug. For researchers tracking the field, the key takeaway lies in the data: the FDA stresses that it is seeking high-quality evidence, noting that thorough product characterization and structured follow-up are precisely what existing reports frequently lack. You can find broader context on this research in our guide to iboga and ibogaine.
Source
- FDA. FDA Seeks Public Input to Support Ibogaine Research. FDA press release, October 5, 2026. Docket details in the Federal Register (91 FR 63563), October 6, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
